title: PHARMAC responds on treatments for pulmonary arterial hypertension.
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Dilky
authors.initials: D
authors.lastname: Rasiah
authors.forename: Sean
authors.initials: S
authors.lastname: Dougherty
mesh_terms: D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use*; D000077300:Bosentan; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D009313:National Health Programs / Q000191:economics; D009520:New Zealand; D013449:Sulfonamides / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan